NOTE FROM DR. STEVENS.
نویسندگان
چکیده
منابع مشابه
A Note to Dr. Winternitz
Among the medical schools responsible for the surge forward of American Medicine in the first third of this century, the Yale Medical School has taken a special place. More than anyone you are responsible for the accomplishments and the continuing intellectual tradition of that school. To an admirable degree you have justified the trust placed in you that you would insist on putting your convic...
متن کاملStevens-Johnson syndrome and toxic epidermal necrolysis in Dr. Hasan Sadikin General Hospital Bandung, Indonesia from 2009-2013
BACKGROUND Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCAR) with high mortality and have a significant public health impact because of high mortality and morbidity. OBJECTIVE To describe data the epidemiological features, etiology, and treatment of retrospectively reviewed data of all patients with SJS and TEN. METHODS Retrosp...
متن کاملNote on Dr. D. W. Montgomery's Case of Teratoma
Through the cou~esy of Dr. Montgomery I have been permitted to study sections from his tumor and to make (1) a note upon the nervous tissue present, and (2) some remarks concerning the theories which have been advanced to explain teratomala in general. I. The tumor contains large masses of nervous "tissue distributed throughout its substance. While most of this nerve tissue resembles embryonic ...
متن کاملRebuttal Comments from Dr. Dunn and Dr. Wechsler
I ntroduction: In recent years a number of emerging new therapies have become available for the treatment of severe asthma among which bronchial ther-moplasty is the only nonpharmacologic intervention that has been approved by the United States Food and Drug Administration in 2010. 1 Although bronchial thermoplasty has great promise for the patient with severe asthma and is now within the thera...
متن کاملLetter from Dr. Kenneth Wilson
The conclusions reached in this review are based on incomplete data. In June 2002, the Melanoma Disease Site Group (DSG) sent me a draft manuscript of the above paper to review. I specifically recommended that the proposed guideline should reflect the fact that the E1684 trial is negative for overall survival benefit for high-dose interferon (HDIFN) at a median follow-up of 12.6 years (one-side...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet
سال: 1831
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(02)94182-6